nach oben

Erschienen in:

01.07.2005 | Original Research Article

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

verfasst von: Dr Bernd Brüggenjürgen, Dagmar Selim, Peter Kardos, Kai Richter, Claus Vogelmeier, Stephanie Roll, Wolfgang Meyer-Sabellek, Roland Buhl, Stefan N. Willich

Erschienen in: PharmacoEconomics | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Objectives: To compare the costs and effectiveness of adjustable maintenance dosing with budesonide/formoterol in a single inhaler versus fixed dosing in adults with asthma.

Methods: In this prospective, randomised, open-label, parallel-group, multicentre trial conducted in Germany, patients with asthma received budesonide/formoterol 160µg/4.5µg in a single inhaler (Symbicort® Turbuhaler®) with two inhalations twice daily for a 4-week run-in period. Patients were then randomised to either adjustable maintenance dosing (one inhalation twice daily, stepping up to four inhalations twice daily for 1 week if asthma worsened; n = 1679) or fixed dosing (two inhalations twice daily; n = 1618) for 12 weeks. The primary efficacy variable was the change in health-related quality of life (HR-QOL), measured using the Asthma Quality of Life Questionnaire (standardised) during the randomised treatment period. Resource utilisation data were collected in parallel and combined with German unit costs to estimate direct and indirect costs (year 2001 values).

Results: Both treatment regimens were equally effective in maintaining HR-QOL and asthma control during the randomised treatment period. However, overall, patients in the adjustable maintenance dosing group took fewer daily inhalations of budesonide/formoterol than those in the fixed-dosing group (mean: 2.63 vs 3.82 inhalations; p < 0.001). Adjustable maintenance dosing was associated with significantly lower asthma-related direct costs compared with fixed dosing (mean: €221 vs €292; p < 0.001). This pattern was maintained when patients were stratified into those with peak expiratory flow (PEF) of 60% to <80% predicted normal and those with PEF of ≥80% predicted normal and when total costs were considered.

Conclusion: Adjustable maintenance dosing with budesonide/formoterol in a single inhaler maintained HR-QOL in adult patients with asthma at a significantly lower cost than fixed dosing.

The use of trade names is for product identifcation purposes only and does not imply endorsement.

World Health Organization. Bronchial asthma: WHO fact sheet number 206 [online]. Last updated January 2000. Available from URL: http://www.who.int/inf-fs/en/fact206.html [Accessed 2003 Aug 13]

Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Fur Respir J 1996; 9: 636–42CrossRef

Jacobson L, Herrzman P, Löfdahl CG, et al. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000; 94: 247–55PubMedCrossRef

Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985–1994. J Allergy Clin Immunol 2000; 106: 493–9PubMedCrossRef

Weissflog D, Matthys H, Virchow JC Jr. Epidemiology and costs of bronchial asthma and chronic bronchitis in Germany [in German]. Dtsch Med Wochenschr 2001; 126: 803–8PubMedCrossRef

Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: WHO/NHLBI Workshop report. National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI). Publication Number 02-3659, 2002

British Thoracic Society (BTS). Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma. Thorax 2003; 58 Suppl. 1: i1–i94

Mygind N. The common cold as a trigger of asthma. Monaldi Arch Chest Dis 2000; 55: 478–83PubMed

Hoskins G, McCowan C, Neville RG, et al. Risk factors and costs associated with an asthma attack. Thorax 2000; 55: 19–24PubMedCrossRef

10.

Andersson F, Borg S, Stahl E. The impact of exacerbations on the asthmatic patient’s preference scores. J Asthma 2003; 40: 615–23PubMedCrossRef

11.

Lahdensuo A. Guided self management of asthma: how to do it. BMJ 1999; 319: 759–60PubMedCrossRef

12.

Partridge MR. Self-management in adults with asthma. Patient Educ Couns 1997; 32 Suppl. 1: S1–4CrossRef

13.

Gibson PG, Talbot PI, Toneguzzi RC. Self-management, autonomy and quality of life in asthma. Chest 1995; 107: 1003–8PubMedCrossRef

14.

Sawyer SM. Action plans, self-monitoring and adherence: changing behaviour to promote better self-management. Med J Aust 2002; 177: S72–4PubMed

15.

Thoonen BP, Schermer TR, van den Boom G, et al. Selfmanagement of asthma in general practice, asthma control and quality of life: a randomised controlled trial. Thorax 2003; 58: 30–6PubMedCrossRef

16.

Lawrence G. Asthma self-management programs can reduce the need for hospital-based asthma care. Respir Care 1995; 40: 39–43PubMed

17.

Ghosh CS, Ravindran P, Joshi M, et al. Reductions in hospital use from self-management training for chronic asthmatics. Soc Sci Med 1998; 46: 1087–93PubMedCrossRef

18.

Ställberg B, Olsson P, Jörgensen LA, et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003; 57: 656–61PubMed

19.

Liljas B, Lahdensuo A. Is asthma self-management cost-effective? Patient Educ Couns 1997; 32 Suppl. 1: S97–S104PubMedCrossRef

20.

Lahdensuo A, Haahtela T, Herrala J, et al. Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ 1998; 316: 1138–9PubMedCrossRef

21.

Schermer TR, Thoonen BP, van den Boom G, et al. Randomized controlled economic evaluation of asthma self-management in primary health care. Am J Respir Crit Care Med 2002; 166: 1062–72PubMedCrossRef

22.

Courts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992; 67: 332–3CrossRef

23.

Partridge MR. Asthma: guided self management. BMJ 1994; 308: 547–8PubMedCrossRef

24.

Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–4PubMedCrossRef

25.

Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler® is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101: 457–63PubMedCrossRef

26.

Schreurs AJ, Sinninghe Damste HE, de Graaff CS, et al. A doseresponse study with formoterol Turbuhaler as maintenance therapy in asthmatic patients. Fur Respir J 1996; 9: 1678–83CrossRef

27.

Ringdal N, Derom E, Wahlin-Boll E, et al. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med 1998; 92: 1017–21PubMedCrossRef

28.

Buhl R, Kardos P, Baare A, et al. Adjustable dosing with budesonide/formoterol in asthma maintains HRQL at a lower drug load than fixed dosing. Curr Med Res Opin 2004; 20: 1209–20PubMedCrossRef

29.

American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive airway disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225–44

30.

Juniper EF, Buist SB, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 155: 1265–70CrossRef

31.

Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81–7PubMedCrossRef

32.

Rutherford C, Mills R, Gibson PG, et al. Improvement in healthrelated quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. Respirology 2003; 8: 371–5PubMedCrossRef

33.

Schmier J, Leidy NK, Gower R. Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. J Asthma 2003; 40: 383–93PubMedCrossRef

34.

Statistisches Jahrbuch 2001 — Für die Bundesrepublik Deutschland. Wiesbaden: Statistisches Bundesamt, 2001: 604 ff

35.

Statistisches Taschenbuch Gesundheit 2002. Bonn/Wiesbaden: Bundesministerium für Gesundheit/Statistisches Bundesamt, 2002, Table 7.7 [online]. Available from URL: http://www.bmgs.bund.de/download/statistiken/stattb2002/lnhalt.htm [Accessed 2005 May 25]

36.

Rote Liste — Arzneimittelverzeichnis für Deutschland. Aulendorf: ECV Editio Cantor Verlag, 2001

37.

Einheitlicher Bewertungsmassstab (EBM). Cologne: Deutscher Aerzte Verlag, 2001

38.

Schwabe U, Paffrath D. Arzneiverordnungs-Report 2001. Berlin: Springer-Verlag, 2001CrossRef

39.

Jacobs JE, van de Lisdonk EH, Smeele I, et al. Management of patients with asthma and COPD: monitoring quality of life and the relationship to subsequent GP interventions. Fam Pract 2001; 18: 574–80PubMedCrossRef

40.

Desikan R, Mason HL, Rupp MT, et al. Health-related quality of life and healthcare resource utilization by COPD patients: a comparison of three instruments. Qual Life Res 2002; 11: 739–51PubMedCrossRef

41.

Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world: effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15: 423–34PubMedCrossRef

42.

FitzGerald M, Sears MR, Boulet L-P, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a 5-month multicenter Canadian study. Can Respir J 2003; 10: 427–34PubMed

43.

Aalbers R, Backer V, Kava TTK, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20: 225–40PubMedCrossRef

Titel: Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma
verfasst von: Dr Bernd Brüggenjürgen
Dagmar Selim
Peter Kardos
Kai Richter
Claus Vogelmeier
Stephanie Roll
Wolfgang Meyer-Sabellek
Roland Buhl
Stefan N. Willich
Publikationsdatum: 01.07.2005
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 7/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523070-00006

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2005

Discounting health effects in pharmacoeconomic evaluations

The state of patient-reported outcomes in atrial fibrillation

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK

The authors’ reply

Evaluating health-related quality-of-life studies in paediatric populations

Costs and medical care consequences associated with the diagnosis of peripheral arterial disease